Cliquez pour voir le graph
Connexions
Cliquez pour voir la ligne de temps
Ligne de temps
Projets
Anciennes Équipes
Publications
Télécharger-
2024Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies, Pathogens and Immunity, 2024, 10 (1), pp.1-11. ⟨10.20411/pai.v10i1.752⟩.
-
2024Levels and functionality of Pacific Islanders’ hybrid humoral immune response to BNT162b2 vaccination and delta/omicron infection: A cohort study in New Caledonia., PLoS Med 2024 Sep; 21(9): e1004397.
-
2024Serological responses against seasonal influenza viruses in patients with multiple myeloma treated or untreated with daratumumab after two doses of tetravalent vaccine, International Journal of Infectious Diseases, 2024, 146, pp.107108. ⟨10.1016/j.ijid.2024.107108⟩.
-
2024Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023-24: a modelling study., Lancet Child Adolesc Health 2024 Aug; (): .
-
2024COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans, JAMA Network Open, 2024, 7 (7), pp.e2419258. ⟨10.1001/jamanetworkopen.2024.19258⟩.
-
2024COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans., JAMA Netw Open 2024 Jul; 7(7): e2419258.
-
2024Serological responses against seasonal influenza viruses in patients with multiple myeloma treated or untreated with daratumumab after two doses of tetravalent vaccine., Int J Infect Dis 2024 May; 146(): 107108.
-
2024COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022, Eurosurveillance, 2024, 29 (13), pp.2300403. ⟨10.2807/1560-7917.es.2024.29.13.2300403⟩.
-
2024COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022., Euro Surveill 2024 Mar; 29(13): .
-
2024Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024, Eurosurveillance, 2024, 29 (8), ⟨10.2807/1560-7917.es.2024.29.8.2400089⟩.
-
+Voir la liste complète de publications